Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023

Posted: May 1, 2023 at 12:18 am

THE WOODLANDS, Texas, April 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2023 financial results on Tuesday, May 2, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.

Original post:
Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023

Related Post

Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights - March 1st, 2024
Gritstone bio Announces Workforce Reduction - March 1st, 2024
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - March 1st, 2024
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results - March 1st, 2024
ProKidney to Participate in Jefferies Biotech on the Bay Summit - March 1st, 2024
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance - March 1st, 2024
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004) - March 1st, 2024
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates - March 1st, 2024
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook - March 1st, 2024
Prelude Therapeutics to Participate in Barclays Global Healthcare Conference - March 1st, 2024
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC - March 1st, 2024
Certara Reports Fourth Quarter 2023 Financial Results - March 1st, 2024
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update - March 1st, 2024
Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference - March 1st, 2024
GENFIT Announces Revenues and Cash Position as of December 31, 2023 - March 1st, 2024
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau - March 1st, 2024
Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results - March 1st, 2024
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results - March 1st, 2024
Spectral AI Appoints Peter M. Carlson as CEO - March 1st, 2024
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference - March 1st, 2024
Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the... - February 21st, 2024
PharmAla Data to be Published in ACS Chemical Neuroscience - February 21st, 2024
ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge... - February 21st, 2024
AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation - February 21st, 2024
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting - February 21st, 2024
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference - February 21st, 2024
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00... - February 21st, 2024
SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024 - February 21st, 2024
NGM Bio to Participate in the Cowen 44th Annual Health Care Conference - February 21st, 2024
NurExone’s Intellectual Property Portfolio Expands - February 21st, 2024
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market - February 21st, 2024
Arvinas Announces Chief Financial Officer Transition - February 21st, 2024
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - February 21st, 2024
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress - February 21st, 2024
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024 - February 21st, 2024
Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq. - February 21st, 2024
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 - February 21st, 2024
PolTREG appoints Dan Shelly as Chief Business Development Officer - February 21st, 2024
Sanofi: Information concerning the total number of voting rights and shares - January 2024 - February 21st, 2024
Bavarian Nordic delivered record financial results in 2023 - February 21st, 2024
Vistin Pharma ASA: Dividend of NOK 0.75 per share - January 14th, 2024
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status - January 14th, 2024
Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR 31... - January 14th, 2024
Key information relating to the cash dividend to be paid by Vistin Pharma ASA - January 14th, 2024
QIAGEN N.V. to release results for Q4 2023 and hold webcast - January 14th, 2024
Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries - January 14th, 2024
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split - January 14th, 2024
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference - January 14th, 2024
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference - January 14th, 2024
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference - January 14th, 2024
Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study - January 14th, 2024
Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2024 Annual General Meeting - January 14th, 2024
Boehringer expands production site in Greece for new medicine - January 14th, 2024
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to... - January 14th, 2024
Voting Rights and Shares Capital of the Company - January 14th, 2024
Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom - January 14th, 2024
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference - January 14th, 2024
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO - January 14th, 2024
Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole - January 14th, 2024
Medicenna Announces Appointment of New Auditor - January 14th, 2024
Axial Therapeutics to Present at Upcoming Conferences - January 6th, 2024
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million - January 6th, 2024
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea - January 6th, 2024
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference,... - January 6th, 2024
Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones - January 6th, 2024
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T... - January 6th, 2024
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders - January 6th, 2024
Kriya Announces Gene Therapy Program for Thyroid Eye Disease - January 6th, 2024
Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis - January 6th, 2024
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024 - January 6th, 2024
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024 - January 6th, 2024
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital - January 6th, 2024
ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD) - January 6th, 2024
BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to... - January 6th, 2024
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones - January 6th, 2024
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development - January 6th, 2024
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program - January 6th, 2024
Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024 - January 6th, 2024
Societal CDMO Reports Inducement Grants for New Staff - January 6th, 2024
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - January 6th, 2024